The percentages of cancers at the advanced T stage (T3 or more) and advanced N stage (N2 or more) were significantly higher in the CD271 strong group than in the moderate-to-weak group (47.2% vs 23.4%: p = 0.023, and 69.4% vs 40.4%: p = 0.009, respectively). This evidence concerns the gene NGFR and cancer.